Conclusion: The conventional cefazolin dose still can result in satisfactory clinical cure rates for bacteremic episodes due to K. pneumoniae with cefazolin MIC 2 mg/mL, the revised susceptible breakpoint of CLSI 2011.
Background:
The Clinical and Laboratory Standards Institute (CLSI) revised the susceptibility breakpoints of cephalosporins for Enterobacteriaceae in 2010 and 2011. However, there is a lack of clinical data about the correlation of minimum inhibitory concentrations (MICs) and clinical outcome. Data for the distribution of MICs and clinical outcomes were analyzed in this study to evaluate the impact of changes in the CLSI breakpoints on the treatment of Klebsiella pneumoniae bacteremia. Methods: Ninety-seven bacteremic K. pneumoniae isolates from Taichung Veterans General Hospital, Taichung, Taiwan were collected for study during the period 2009e2011. The cefazolin MIC was determined by the broth microdilution method according to the recommendations of the CLSI. The MIC distribution of cefazolin and the clinical responses to definitive cefazolin treatment were analyzed. Results: The modal cefazolin MIC among the 97 isolates was 1 mg/mL and accounted for 73 (75.3%) isolates. There were 18 (18.6%) isolates with a cefazolin MIC of 2 mg/mL. The conventional dosage regimens of cefazolin (1 g every 6 hours or 8 hours) achieved a clinical cure in 70 (97.2%) of 72 patients in the group with a cefazolin MIC 1 mg/mL and in 14 (87.5%) of 16 patients in the group with a cefazolin MIC of 2 mg/mL. With the conventional dose, the cumulative clinical cure rate for K. pneumoniae bacteremia with cefazolin MIC 2 mg/mL was 95.5% (84/88 patients).
Introduction
Klebsiella pneumoniae is a common pathogen that causes urinary tract infections, 1 biliary tract infections, 2 liver abscesses, 3, 4 pneumonia, 5, 6 and bacteremia. 7 The reported case fatality rates of K. pneumoniae bacteremia are 20e40%. 4,8e10 Before 2010, the breakpoints of cephalosporins for Enterobacteriaceae had been set for several decades. 11 As a result of the growing prevalence of extended spectrum beta-lactamase (ESBL)-producing isolates around the world, 12, 13 screening and confirmatory tests for ESBLs in K. pneumoniae and Escherichia coli were developed by the National Committee for Clinical Laboratory Standards in 1999.
14 Based on an evaluation of the microbiological data, clinical outcomes, and pharmacodynamic-pharmacokinetic (PK-PD) properties for susceptibility breakpoints, the Clinical and Laboratory Standards Institute (CLSI) performance standards in 2010 revised the interpretive criteria for cephalosporins and aztreonam. 15 The minimum inhibitory concentration (MIC) breakpoints for cefazolin were revised in 2010: the susceptible breakpoint changed from 8 mg/mL to 1 mg/mL, the intermediate breakpoint from 16 mg/mL to 2 mg/mL, and the resistant breakpoint from !32 mg/mL to !4 mg/mL. 15 However, using the CLSI breakpoints published in 2010, the strains with cefazolin MICs of 2e8 mg/mL are regarded as intermediate or resistant to cefazolin. Consequently, this revision would preclude the use of cefazolin, a conventionally effective drug, for the prevention and treatment of infection caused by Enterobacteriaceae that do not have a resistance mechanism. 11 To prevent this impact, the breakpoints of cefazolin for Enterobacteriaceae was further revised by the CLSI in 2011 (susceptible, 2 mg/mL; intermediate, 4 mg/mL; and resistant, !8 mg/mL), according to Monte Carlo simulations of PK-PD data and recent laboratory data.
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To define the microbiological breakpoints which differentiate wild-type strains from those with resistance mechanisms, moderate to large numbers of in vitro MIC tests are needed to provide the patterns of MIC distribution. 11 However, there is a lack of data on the natural antibiotic MIC distribution of K. pneumoniae. 16, 17 A few published clinical studies on the treatment of urinary tract infections caused by Enterobacteriaceae with cefazolin have been conducted. 18, 19 The dose and frequency of the regimen varied widely among the studies.
18e21 Data about the correlation of MIC and cephalosporin dose from clinical trials are also lacking. 
Materials and methods

Bacterial strains
During the period from January 2009 to December 2011, 721 K. pneumoniae non-duplicate isolates from blood specimens were identified at the Microbiology Laboratory of Taichung Veterans General Hospital, Taichung, Taiwan. The susceptibility tests of these isolates were performed by the disk diffusion method and read according to the CLSI 2009 recommendations. 22 There were 630 isolates susceptible to cefazolin and 91 isolates resistant to cefazolin (using the disk diffusion test, including the double-disk diffusion method of the CLSI 2009 ESBL confirmatory test 22 ). The medical records were reviewed for all 721 patients with K. pneumoniae bacteremia. Only 97 patients with bacteremia due to cefazolin-susceptible isolates (disk diffusion test, CLSI 2009 22 ) were included with the condition that cefazolin had been initiated within 2 days of the report of K. pneumoniae bacteremia and used for at least 7 days. These 97 isolates were selected for the MIC study. Among 91 cefazolin-resistant isolates, only 82 isolates were available for MIC tests.
Susceptibility test
The cefazolin MICs were measured by the broth microdilution method according to the CLSI recommendations.
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E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the quality control strains. The susceptibility breakpoints of cefazolin were 8 mg/mL, 1 mg/mL, 2 mg/mL, according to the CLSI recommendations issued in 2009, 22 2010, 15 and 2011, 28 respectively.
Clinical and bacteriological assessments
The clinical outcomes of the 179 patients with bacteremia of K. pneumoniae (97 cefazolin-susceptible and 82 cefazolin-resistant, selected by the disk diffusion tests according to CLSI 2009 22 ) were analyzed by a review of the medical records. The clinical conditions (such as age, sex, source of infection, length of stay, days to defervescence after antimicrobial treatment, clinical response, and death) associated with the acquisition of K. pneumoniae bacteremia were reviewed. The efficacy was assessed by the clinical and bacteriological response. 24 The clinical response was evaluated at the end of antimicrobial treatment and defined as cure (disappearance of acute signs and symptoms related to the infection or sufficient improvement such that additional or alternative antimicrobial treatment was not required), failure (insufficient improvement of the signs and symptoms of infection and additional or alternative antimicrobial treatment was required), or indeterminate (a clinical assessment was not possible for any reason). The bacteriological response was evaluated at the 7 th day after the discontinuation of antimicrobial treatment and defined as eradication (no more positive blood cultures yielded), presumed eradication (absence of evaluable culture in a patient with clinical cure), persistence (presence of baseline pathogen in a patient with clinical failure of treatment), presumed persistence (absence of evaluable culture in a patient with clinical failure of treatment), or indeterminate (if bacteriological response was not evaluable for any reason). Bacteriological success was defined if eradication or presumed eradication were present. Bacteriological failure was rated as persistence or presumed persistence. The 14-day mortality rates after bacteremia were analyzed.
The clinical characteristics and outcomes of these 97 patients with K. pneumoniae bacteremia were classified into three groups according to cefazolin MICs: 1 mg/mL, 2 mg/mL, and 4e8 mg/mL.
Statistical analysis
Categorical variables were analyzed by two-tailed c 2 test; continuous variables were analyzed by the Student t test and analysis of variance test. p < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS version 22.0.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
During the study period, 97 clinically evaluable patients with cefazolin-susceptible K. pneumoniae bacteremia were treated with cefazolin. The MICs for the 97 isolates were 8 mg/mL, including 1 mg/mL for 75 (77.3%) isolates, 2 mg/ mL for 18 (18.6%) isolates, and 4e8 mg/mL for four (4.1%) isolates (Fig. 1) . The clinical characteristics and outcomes of 97 patients with K. pneumoniae bacteremia (classified into three groups, cefazolin MIC 1 mg/mL, 2 mg/mL, and 4e8 mg/ mL) are given in Table 1 . There was no statistically significant difference in the demographic characteristics and outcomes among the three groups, except for skin and soft tissue infection and length of stay in hospital. The length of stay in hospital in the three groups of cefazolin MIC 1 mg/mL, 2 mg/ mL, and 4e8 mg/mL were 17 AE 1.1 days, 25 AE 3.5 days, and 34 AE 9.6 days, respectively. There were statistically significant differences in the length of stay among these three groups (p < 0.05). The patients in the group with a higher MIC had longer lengths of stay (p < 0.05). The periods to defervescence in the three groups of cefazolin MIC 1 mg/mL, 2 mg/mL, and 4e8 mg/mL were 2.2 AE 0.1 days, 1.3 AE 0.1 days, and 1.6 AE 0.3 days, respectively (p Z 0.056). The duration of treatment in the three groups of cefazolin MIC 1 mg/mL, 2 mg/mL, and 4e8 mg/mL were 12.8 AE 0.7 days, 14.3 AE 2.3 days, and 15 AE 3.2 days, respectively (p Z 0.634).
There were 25 patients with K. pneumoniae bacteremia and liver abscess. Among 25 isolates from patients with liver abscess, there were 20 isolates with cefazolin MIC 1 mg/mL, four isolates with a cefazolin MIC of 2 mg/mL, and one isolate with a cefazolin MIC of 4 mg/mL. All patients with K. pneumoniae bacteremia and liver abscess were clinically cured.
All 97 isolates were negative for the double-disk diffusion method of the ESBL confirmatory test. The modal cefazolin MIC was 1 mg/mL and accounted for 73 (75.3%) isolates. The cumulative percentage for MIC 2 mg/mL was 95.9%.
Cefazolin MICs of 82 cefazolin-resistant isolates (by disk diffusion test, CLSI 2009 22 ) ranged from 16 mg/mL to >256 mg/mL, including 16 mg/mL for two isolates; 32 mg/mL for five isolates; 64 mg/mL for one isolate; 128 mg/mL for seven isolates; 256 mg/mL for two isolates; and >256 mg/mL for 65 (79.3%) isolates. The 82 patients with cefazolin-resistant K. pneumoniae bacteremia were treated with carbapenem, fluoroquinolones, or third-generation cephalosporins.
The rates of clinical cure were 97% (73/75), 88.9% (16/ 18), 100% (3/3), and 100% (1/1) for the patients in the groups with cefazolin MICs of 1 mg/mL, 2 mg/mL, 4 mg/mL, and 8 mg/mL, respectively (Fig. 1) . Table 2 gives the rates of clinical cure correlated with the MIC and dosage regimen. Among 72 patients in the group with cefazolin MIC 1 mg/mL and treated with the conventional dose (cefazolin given as 1 g every 6 hours or 8 hours), the rate of clinical cure was 97.2%. During antimicrobial treatment, one patient died as a result of arrhythmia with sudden death and the other died from terminal lung cancer with multiple organ failure. Although clinical improvement was observed in these two patients, clinical cure was not achieved due to death before the end of the scheduled antimicrobial treatment. Among 16 patients in the group with a cefazolin MIC of 2 mg/mL and treated with the conventional dose (cefazolin given as 1 g every 6 hours or 8 hours), the rate of clinical cure was 87.5% (14/16 patients). Two patients died from liver cirrhosis and lung cancer with multiple organ failure, respectively, before the end of the scheduled antimicrobial treatment. Five patients were treated with cefazolin 1 g every 12 hours as a result of renal insufficiency and one patient with cefazolin 0.5 g every day as a result of uremia. The bacteriological success rate was 100% for all 93 patients with a complete course of treatment with cefazolin. The patients in the group with cefazolin MIC 8 mg/mL had a lower 14-day mortality rate than those in the group with cefazolin MIC >8 mg/mL (4.1% vs. 47.5%; p < 0.001).
Discussion
The breakpoints of cefazolin for Enterobacteriaceae revised by the CLSI in 2010 15 were 1 mg/mL as susceptible, 2 mg/mL intermediate, and !4 mg/mL resistant. Accordingly 22 (22.7%) of 97 isolates with cefazolin MICs of 2e8 mg/mL in the current study would fall into the intermediate or resistant categories. However, the clinical outcome of these 22 patients was evaluated as achieving clinical cure and bacteriological eradication, arguing for the latest susceptible breakpoint of cefazolin, i.e., 2 mg/mL. From the viewpoint of the microbiological data, the modal cefazolin MIC among 97 cefazolin-susceptible isolates in this study was 1 mg/mL and accounted for 73 (75.3%) isolates. The cumulative percentage for MIC 2 mg/mL was 95.9%. If the susceptibility breakpoint was 1 mg/mL (CLSI 2010 15 ), 18.6% of isolates with MIC of 2 mg/mL would be interpreted as intermediate. This would result in a great Table 1 Comparison of clinical characteristics and outcomes of 97 patients with Klebsiella pneumoniae bacteremia, classified by cefazolin minimum inhibitory concentration of the bacteremic isolate: 1 mg/mL, 2 mg/mL, and 4e8 mg/mL
Clinical characteristic
Cefazolin MIC (mg/mL) p impact on the choice of cefazolin for the treatment of Enterobacteriaceae infections. Hence, we examined data from other studies before interpretating our data. The MIC distribution of wild-type microorganisms are available on the EUCAST website. 25 Of 208 wild-type K. pneumoniae isolates, there were 71 (34.1%) isolates had a cefazolin MIC of 1 mg/mL and 82 (39.4%) isolates had an MIC of 2 mg/mL. The cumulative percentage for MIC 2 mg/mL was 73.6%. In another study conducted in the Mayo Clinic (Rochester, MN, USA), 199 consecutive clinical isolates of E. coli (n Z 180), K. pneumoniae (n Z 8), and Klebsiella oxytoca (n Z 11) were studied for their cephalosporin MIC. 16 Among the 191 isolates without acquired secondary b-lactamases (ESBL or AmpC), there were 34 (17.8%) isolates with a cefazolin MIC of 1 mg/ mL and 98 (51.3%) isolates with a cefazolin MIC of 2 mg/mL. 16 The cumulative percentage for MIC 2 mg/mL was 69.1%. The cumulative percentages of the isolates with MIC 2 mg/mL ranged from 69.1% to 95.9%, accounting for the majority of isolates without a resistance mechanism in these three studies. Hence it is reasonable to revise the interpretive criteria of cefazolin from 1 mg/mL (CLSI 2010 15 ) to 2 mg/mL (CLSI 2011 28 ) based on these microbiological data. According to PK-PD data, the cefazolin susceptibility breakpoint of 2 mg/mL based on a higher dosage regimen (2 g every 8 hours) was suggested by CLSI 2011. 28 The decision for the revised breakpoints by CLSI 2011 28 was based on the Monte Carlo simulation analysis. 26, 27 The target attainment rates for 50% T > MIC can achieve 94% for the isolates with a cefazolin MIC of 1 mg/mL and 64% for those of 2 mg/mL at the conventional dose regimen of 1 g every 8 hours. 26 Therefore the susceptibility breakpoint of cefazolin was determined as 1 mg/mL for the conventional dose regimen (1 g every 8 hours) by CLSI 2010. 15 However, the target attainment rates would achieve 100% for the isolates with a cefazolin MIC of 1 mg/mL and 94% for those of 2 mg/mL at a higher cefazolin dose (2 g every 8 hours). 26 Therefore the interpretive criteria for cefazolin in the CLSI 2011 28 were revised (susceptible, 2 mg/mL; intermediate, 4 mg/mL; and resistant, !8 mg/mL) based on a higher dose regimen.
The clinical outcome data, as well as the microbiological data, should be evaluated to determine the optimum susceptibility breakpoint of cefazolin. The conventional dose regimens of cefazolin (1 g every 6 hours or 8 hours) achieved clinical cure in 97.2% of 72 patients in the group with a cefazolin MIC 1 mg/mL and in 87.5% of 16 patients in the group with a cefazolin MIC of 2 mg/mL. With conventional doses, the rate of clinical cure for bacteremia of K. pneumoniae with cefazolin MIC 2 mg/mL was 95.5%. Such study findings can support the revised cefazolin susceptibility breakpoint of 2 mg/mL (CLSI 2011 28 ). There were some limitations in this study. First, a relatively small number of patients, especially those in the group with a cefazolin MIC of 4e8 mg/mL, was not sufficient to demonstrate significant associations between cefazolin MIC and clinical outcome, although they were successfully treated with cefazolin. Second, the 30-day mortality was not analyzed, because the patients were treated with a mean duration of 13.1 days and a mean hospital stay of 20.3 days. Third, although clinical cure was achieved in all 25 patients with liver abscess and cefazolin treatment, the number of patients was limited and this study focused on the clinical response of definitive cefazolin treatment without the inclusion of critically ill patients. Cefazolin in conventional dose regimens has been used for liver abscess for decades. 29 The role of cefazolin treatment for systemic infections due to K. pneumoniae with cefazolin MIC 2 mg/ mL warrants further clinical studies.
In conclusion, conventional cefazolin dosage (1 g every 6 hours or 8 hours) can result in satisfactory clinical cure rates of bacteremic episodes due to K. pneumoniae with cefazolin MIC 2 mg/mL. Such clinical data argue for the latest cefazolin-susceptible breakpoint of 2 mg/mL based on a higher dose regimen.
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